BACKGROUND Neprilysin is a membrane-bound enzyme that breaks down natriuretic peptides. The PARADIGM-HF
in patients with hypertension (5) and with heart failure (HF) with preserved ejection fraction (6) Neprilysin is a membrane-bound enzyme with a large extracellular catalytic domain, a single transmembrane region, and a short (27 amino acids) cytoplasmic N-terminal domain (8, 9) . Previous studies showed that neprilysin, like many other membranebound metalloproteases, can be released from the cell surface, producing a nonmembrane-associated form that retains catalytic activity (10, 11) . Previous reports have identified neprilysin in biological fluids (12, 13) , but no evidence exists of circulating neprilysin as a pathobiological surrogate in patients with HF. Accordingly, our aim was to assess for the first time the presence of circulating soluble neprilysin in a real-life cohort of HF patients and to correlate neprilysin levels with outcomes.
METHODS STUDY POPULATION.
Ambulatory patients treated at a multidisciplinary HF clinic between May 22, 2006 and May 22, 2013 were consecutively included in the study. Referral inclusion criteria and blood sample collection have been described elsewhere (14) . In summary, patients were referred to the HF clinic by cardiology or internal medicine depart- FOLLOW-UP AND OUTCOMES. All patients were followed up at regular pre-defined intervals, with additional visits as required in case of decompensation.
The regular visitation schedule included a minimum of quarterly visits with nurses, biannual visits with physicians, and elective visits with geriatricians, psychiatrists, and rehabilitation physicians (14, 15) .
Patients who did not attend the regular visits were contacted by telephone. available in 803 patients) were also included in a multivariable analysis.
Finally, we used different measurements of performance to test the potential incremental prognostic value of neprilysin (discrimination, calibration, and reclassification) as described previously (18) . For net reclassification improvement calculation, we used risk categories based on tertiles of risk for the composite endpoint (<21%, 21% to 39%, and >39%) and cardiovascular death (<11%, 11% to 23%, and >23%). Figure 2 illustrates the diverging Bayés-Genís et al. and NT-proBNP (considered the baseline model) had little impact on discrimination but substantially improved calibration and reclassification (Table 3) .
Moreover, likelihood ratios showed a better global goodness of fit of the model that included neprilysin Neprilysin ≥ median Neprilysin < median
In this analysis, age is included as a covariate and the median value of neprilysin is 0.642 ng/ml. Both the event-free survival curve for the primary composite endpoint of cardiovascular (CV) death or heart failure (HF) hospitalization (A) and the survival curve for CV death (B) illustrate divergent paths relative to neprilysin median values. A membrane-bound enzyme, neprilysin can be released from the cell surface, producing a non-membrane-associated or soluble form that can be measured in blood samples. Levels of this soluble form are shown for the first time to be related to heart failure (HF) prognosis (right). ANP ¼ atrial natriuretic peptide; BNP ¼ B-type natriuretic peptide; CNP ¼ C-type natriuretic peptide; CV ¼ cardiovascular; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide. (24, 25) . Therefore, BNP might only be used as a diagnostic biomarker after extended treatment with LCZ696, whereas NT-proBNP, which is not a substrate for neprilysin, may therefore be used to assess the effect of LCZ696 on disease state, risk stratification, prognosis, and monitoring. This may also explain the lack of association found here between circulating neprilysin and NT-proBNP levels.
STUDY LIMITATIONS. We only assessed circulating soluble neprilysin, but in humans, neprilysin is widely expressed in the kidney, lung, endothelial cells, vascular smooth muscle cells, cardiac myocytes, fibroblasts, neutrophils, adipocytes, testes, and brain, with the highest concentrations being present in the renal proximal tubules. In lymphocytes, neprilysin expression is developmentally regulated (26) . Thus, the results reported here very likely underrepresent overall neprilysin expression and activity. Moreover, the experimental assay we describe for neprilysin determination has long incubation times, which makes it ill-suited at this time for daily clinical use.
Additionally, the study population was a general HF population treated at a specific multidisciplinary HF unit in a tertiary care hospital; most patients were referred from the cardiology department and thus were relatively young men with HF of ischemic origin and reduced LVEF. As such, these results cannot necessarily be extrapolated to a global HF population. 
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Neprilysin is a crucial enzyme that mediates the up-regulation of the natriuretic peptide axis in patients with HF, and inhibition of neprilysin as a therapeutic target is associated with reductions in cardiovascular morbidity and mortality.
TRANSLATIONAL OUTLOOK: Prospective trials are needed to assess tailored strategies of pharmacological neprilysin inhibition based on measurements of plasma neprilysin levels in patients with HF.
Bayés-Genís et al.
